Terns Pharmaceuticals Inc... (TERN)

NASDAQ: TERN · Real-Time Price · USD

3.56

0.26 (7.88%)

At close: May 01, 2025, 3:59 PM

3.61

1.26%

After-hours: May 01, 2025, 06:06 PM EDT

7.88% (1D)

Bid	3.5
Market Cap	311.22M
Revenue (ttm)	n/a
Net Income (ttm)	-88.85M
EPS (ttm)	-1.12
PE Ratio (ttm)	-3.18
Forward PE	-2.39
Analyst	Buy

Ask	3.65
Volume	1,102,212
Avg. Volume (20D)	1,196,145
Open	3.32
Previous Close	3.30
Day's Range	3.31 - 3.58
52-Week Range	1.86 - 11.40
Beta	-0.14

About TERN

Terns Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops small-molecule single-agent and combination therapy candidates for the treatment of non-alcoholic steatohepatitis (NASH) and obesity. The company develops TERN-101, a liver-distributed and non-bile acid farnesoid X receptor agonist, which is in Phase IIa clinical trial for the treatment of NASH; and TERN-201, a vascular adhesion protein-1 inhibitor that is in Phase ...

[Read more]

Industry Biotechnology

Sector Healthcare

IPO Date Feb 5, 2021

Employees 59

Stock Exchange NASDAQ

Ticker Symbol TERN

Website https://www.ternspharma.com

Full Company Profile

Analyst Forecast

According to 5 analyst ratings, the average rating for TERN stock is "Buy." The 12-month stock price forecast is $20, which is an increase of 461.01% from the latest price.

Stock Forecasts

Why Price Moved

1 month ago

+6.69%

Terns Pharmaceuticals shares are trading higher af... Unlock content with Pro Subscription

7 months ago

-4.9%

Terns Pharmaceuticals shares are trading lower after the company announced it priced a $150.1 million public offering of 11,919,048 shares at $10.50 per share.

News

3 weeks ago · zacks.com

Down -39.83% in 4 Weeks, Here's Why Terns Pharmaceuticals (TERN) Looks Ripe for a Turnaround

Terns Pharmaceuticals (TERN) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts...

4 weeks ago · zacks.com

Down -31.41% in 4 Weeks, Here's Why You Should You Buy the Dip in Terns Pharmaceuticals (TERN)

Terns Pharmaceuticals (TERN) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnin...

1 month ago · zacks.com

All You Need to Know About Terns Pharmaceuticals (TERN) Rating Upgrade to Buy

Terns Pharmaceuticals (TERN) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

1 month ago · fool.com

This Weight Loss Stock Could Skyrocket by 462%, According to Wall Street

Last year, Viking Therapeutics, a mid-cap biotech, made waves after it reported excellent phase 2 results for an investigational medicine for weight loss, the industry's hottest and perhaps fastest-gr...